Medical Cannabis in Parkinson Disease: Real-Life Patients' Experience

@article{Balash2017MedicalCI,
  title={Medical Cannabis in Parkinson Disease: Real-Life Patients' Experience},
  author={Yacov Balash and Lihi Bar-Lev Schleider and Amos D. Korczyn and H. Shabtai and Judith Knaani and Alina Rosenberg and Yehuda Baruch and Ruth Djaldetti and Nir Giladi and Tanya Gurevich},
  journal={Clinical Neuropharmacology},
  year={2017},
  volume={40},
  pages={268–272}
}
Background The use of medical cannabis (MC) is controversial. [...] Key Method Results Forty-seven nondemented patients with PD (40 men) participated. Their mean age was 64.2 ± 10.8 years, mean disease duration was 10.8 ± 8.3 years, median Hoehn and Yahr (H&Y) was stage III. The duration of MC use was 19.1 ± 17.0 months, and the mean daily dose was 0.9 ± 0.5 g. The delivery of MC was mainly by smoking cigarettes (38 cases, 80.9%). Effect size (r2) improvement for falls was 0.89, 0.73 for pain relief, 0.64 for…Expand
Cannabis in Parkinson's Disease: The Patients' View.
TLDR
MC is considered as a therapeutic option by many PD patients, Nevertheless, efficacy and different ROA should further be investigated. Expand
Medical cannabis as an alternative therapeutics for Parkinsons' disease: Systematic review.
TLDR
There is insufficient evidence to reform international legislation regarding cannabis use in PD practice and the positive effects described in uncontrolled studies have not been confirmed by the few and small RCTs. Expand
Cannabis and its derivatives for the use of motor symptoms in Parkinson’s disease: a systematic review and meta-analysis
TLDR
Although observational studies establish subjective symptom alleviation and interest in MC among PD patients, there is insufficient evidence to support its integration into clinical practice for motor symptom treatment. Expand
Medical Cannabis for Older Patients—Treatment Protocol and Initial Results
TLDR
A pragmatic treatment protocol for medical cannabis in older adults is presented, considered carefully and individually for each patient after a risk-benefit analysis and followed by frequent monitoring for efficacy and adverse events. Expand
The Effect of Medical Cannabis on Pain Level and Quality of Sleep among Rheumatology Clinic Outpatients
TLDR
MC had a favorable effect on pain level and quality of sleep among all spectrums of problems at the rheumatology clinic. Expand
The effects of Cannabis on hallucinations in Parkinson's disease patients
TLDR
The number of studies and patients evaluated are too small to make any definite conclusions pointing to the need for more research in this area, but the incidence of hallucinations and delusions during the use of cannabis in PD patients is within the range of prevalence. Expand
Cannabis use assessment and its impact on pain in rheumatologic diseases: a systematic review and meta-analysis.
TLDR
Nearly 20% of patients suffering from rheumatologic diseases actively consume cannabis, with an improvement in pain, and the issue of cannabis use in the management of these patients should be addressed during medical consultation, essentially with cannabis-based standardized pharmaceutical products. Expand
Weeding through the haze: a survey on cannabis use among people living with Parkinson’s disease in the US
TLDR
The results suggest that the lack of formal guidance or research evidence about cannabis for PD may in part underlie inconsistencies in both use and reported effectiveness. Expand
A Survey of Cannabis Acute Effects and Withdrawal Symptoms: Differential Responses Across User Types and Age
TLDR
Older people and medical users appear to experience acute and withdrawal effects of cannabis differently than recreational and younger users, perhaps because these groups benefit more from the medicinal properties of cannabis. Expand
Mental Health and Cognition in Older Cannabis Users: a Review
TLDR
Although preliminary findings suggests that low-dose, short-term medical cannabis does not carry significant risk of serious mental health and cognitive adverse effects in older adults without prior psychiatric history, epidemiological studies find a correlation between past-year cannabis use and poor mental health outcomes in community-dwelling older adults. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 26 REFERENCES
Cannabis (Medical Marijuana) Treatment for Motor and Non–Motor Symptoms of Parkinson Disease: An Open-Label Observational Study
TLDR
The study suggests that cannabis might have a place in the therapeutic armamentarium of PD, with significant improvement of sleep and pain scores and no significant adverse effects of the drug were observed. Expand
Cannabis for dyskinesia in Parkinson disease
TLDR
Orally administered cannabis extract resulted in no objective or subjective improvement in dyskinesias or parkinsonism in Parkinson disease patients. Expand
The perceived effects of smoked cannabis on patients with multiple sclerosis.
TLDR
The survey findings will aid in the design of a clinical trial of cannabis or cannabinoid administration to MS patients or to other patients with similar signs or symptoms. Expand
Discriminating the effects of Cannabis sativa and Cannabis indica: a web survey of medical cannabis users.
TLDR
The two species had different effect associations on symptoms and conditions, possibly because of ingredient differences, in this anonymous Web survey. Expand
The link between dopamine function and apathy in cannabis users: an [18F]-DOPA PET imaging study
TLDR
Findings indicate that the reduction in striatal dopamine synthesis capacity associated with chronic cannabis use may underlie reduced reward sensitivity and amotivation associated with Chronic cannabis use. Expand
Survey on cannabis use in Parkinson's disease: Subjective improvement of motor symptoms
An anonymous questionnaire sent to all patients attending the Prague Movement Disorder Centre revealed that 25% of 339 respondents had taken cannabis and 45.9% of these described some form ofExpand
Marijuana for parkinsonian tremor.
TLDR
The results do not support the notion that cannabis when smoked reduces tremor or any other Parkinsonian disabilities and it may be that its non-specific sedative or anxiolytic actions benefit certain tremulous patients when anxiety is a significant trigger factor. Expand
Buspirone treatment of cannabis dependence: A randomized, placebo-controlled trial.
TLDR
Buspirone was not more efficacious than placebo in reducing cannabis use, and important gender differences were noted, with women having worse cannabis use outcomes with buspirone treatment. Expand
[MEDICAL CANNABIS].
TLDR
As long as cannabis is classified as an illicit drug and until further controlled studies are performed, the use of medical cannabis should be limited to patients who failed conventional better established treatment. Expand
Cannabis Withdrawal, Posttreatment Abstinence, and Days to First Cannabis Use Among Emerging Adults in Substance Use Treatment
TLDR
Emerging adults with DSM-5 cannabis withdrawal may have difficulty initiating abstinence in the days following their intake assessment, implying the need for strategies to mitigate their more rapid return to cannabis use. Expand
...
1
2
3
...